Brief: Celltrion's Anti-Covid 19 Monoclonal Antibody Treatment, Regdanvimab, Demonstrates Neutralising Effect Against South African Variant
29/04/2021 10:03
April 29 (Reuters) - Celltrion Inc 068270.KS :
* CELLTRION'S ANTI-COVID 19 MONOCLONAL ANTIBODY TREATMENT,
REGDANVIMAB (CT-P59), DEMONSTRATES NEUTRALISING EFFECT AGAINST
SOUTH AFRICAN VARIANT (B.1.351)
Source text for Eikon: ID:nBw279G99a
Further company coverage: 068270.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion
See all newsBrief: Celltrion Inc To Acquire 100 Billion Won Worth Of Own Shares
Brief: Celltrion Q1 Operating. Profit 322 Billion Won, Up 115% Y/Y
Brief: Celltrion To Cancel 100 Billion Won Treasury Shares
Brief: Celltrion Plans Phase 3 Clinical Trials For Keytruda Biosimilar With 220 Patients
Brief: Celltrion To Buy 100 Billion Won Of Own Shares